Dome9 Achieves SOC 2 Type 2 Certification MOUNTAIN VIEW,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
53
Dome9 Achieves SOC 2 Type 2 Certification

MOUNTAIN VIEW, CA--(Marketwired - Jan 26, 2017) - Dome9 Security , the leader in cloud infrastructure security, today announced that it has successfully completed a Service Organization Controls (SOC) 2 Type 2 examination related to security, availability and confidentiality principles defined by the American Institute of Certified Public Accountants (AICPA). EY (formerly Ernst & Young), a global leader in assurance, tax, transactions and advisory services, performed a rigorous audit of Dome9's security controls and processes for its products and services. The SOC 2 Type 2 certification was completed less than a year after Dome9 achieved ISO 27001 certification.

"Enterprise customers worldwide rely on the Dome9 platform to manage security and compliance in their public cloud environments," said Zohar Alon, CEO and co-founder of Dome9 Security. "At Dome9, we take this responsibility seriously. We have invested heavily in implementing security controls and practices to ensure that our products and systems meet the highest standards of security and reliability and that our customers' data confidentiality is protected. Dome9 continues to lead the way in earning customer trust at a time when it is most required."

EY's examination for SOC 2 certification included independent testing of controls related to the Dome9 Arc SaaS platform. The SOC 2 Type 2 report indicates that controls were suitably designed and operating effectively over a period of time. These controls meet the criteria for security, availability, processing integrity, confidentiality and privacy defined in Section 100 of Trust Services Principles and Criteria established by the American Institute of CPAs (AICPA), Assurance Services Executive Committee (ASEC).

"Achieving SOC 2 Type 2 compliance is a reflection of Dome9's continued commitment to security and privacy," said Eyal Fingold, vice president, research and development of Dome9 Security. "Over 200 enterprise customers use the Dome9 Arc platform to actively protect their public cloud environments, visualize their network security posture, detect and remediate misconfigurations and manage compliance. The SOC 2 Type 2 report gives our customers assurance that the controls we have in place to keep their data secure and confidential and are designed and operating as intended."

Additional Resources: For a free trial of Dome9: https://secure.dome9.com/Account/Register To learn about Dome9 Arc: https://dome9.com/dome9-arc Follow us on Twitter: @dome9 Connect with us on LinkedIn: https://www.linkedin.com/company/dome9-security

About Dome9 Dome9 delivers verifiable cloud infrastructure security and compliance to all businesses at all times across all public clouds. The Dome9 Arc SaaS platform leverages cloud-native security capabilities and cloud-agnostic policy automation to bring comprehensive network security, advanced IAM protection and continuous compliance to every public cloud environment. Dome9 offers technologies to assess security posture, detect misconfigurations, model gold standard policies, protect against attacks and insider threats, and conform to security best practices in the cloud. Enterprises use Dome9 Arc for faster and more effective cloud security operations, pain-free compliance and governance, and Rugged DevOps practices. Learn more at www.dome9.com .

(C) 2017 Dome9 Security. All rights reserved. Other brand names mentioned herein are for identification purposes only and may be the trademarks of their holder(s).

Media Contact Travis Anderson 10Fold Communications Email Contact 925.271.8227

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 13

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 24

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 24

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 19

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 19

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank Reports Impressive Growth in Financial Performance

Updated Category News Views 237

Inbank's Stellar Financial Performance in Recent Quarters Inbank has achieved significant milestones in its Q2 2025 financial results, showcasing dynamic growth and resilience in a fluctuating market. The bank reported a remarkable originated volume of 196 million euros, marking a 15% increase from the previous year. Although consolidated net profit saw a slight decline...

Continue Reading
Navient Elects Edward Bramson as Chair After Shareholder Meeting

Updated Category News Views 164

Navient's Annual Meeting Marks a New Chapter HERNDON, Va. - Recently, Navient (Nasdaq: NAVI) convened its Annual Meeting of Shareholders, setting the stage for significant leadership changes within the company. This year, shareholders engaged actively, voting to approve three pivotal proposals outlined by the board of directors. This included the election of seven new...

Continue Reading
Annexon Secures $75 Million in Public Stock Offering

Updated Category News Views 184

Overview of Annexon's Recent Public Offering Annexon, Inc. (NASDAQ: ANNX), a pioneering biopharmaceutical firm, recently announced the successful pricing of its public offering aimed at raising $75 million. This exciting event took place as the company continues to push forward with its mission to address neuroinflammation and related diseases, facilitating groundbreaking...

Continue Reading
Werner Enterprises Set for Key Investment Conferences This Year

Updated Category News Views 310

Werner Enterprises is Poised for Investment Conference Engagements Werner Enterprises, Inc. (Nasdaq: WERN), a well-known name in transportation and logistics, is preparing to participate in several significant investment conferences. These events present a fantastic opportunity for the company to share insights about its growth strategies and market position. Upcoming...

Continue Reading
Cunard Achieves Unprecedented Booking Milestones in 2024

Updated Category News Views 156

Record-Breaking Booking Success for Cunard Cunard has recently announced remarkable booking figures for the year 2024, driven by a stellar year and the eagerly awaited introduction of its ship, Queen Anne. This significant increase has resulted in an astonishing 73,000 more guest reservations from January to October compared to the same timeframe in the previous year,...

Continue Reading